This company has been marked as potentially delisted and may not be actively trading. Proteon Therapeutics (PRTO) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsTrendsBuy This Stock PRTO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period ProQR Therapeutics price target raised to $4 from $2.50 at ChardanNovember 9, 2024 | markets.businessinsider.comProtara Therapeutics (TARA) Earnings Dates & ReportsNovember 1, 2024 | investing.comProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesOctober 29, 2024 | markets.businessinsider.comPROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On MondayOctober 28, 2024 | msn.comProQR Announces Major Share Offering AgreementOctober 25, 2024 | markets.businessinsider.comSeaport raises $225m to advance portfolio of neuropsychiatric prodrugsOctober 22, 2024 | msn.comProdrugs and patents: Enhancing therapy adherence and reducing side effectsSeptember 11, 2024 | msn.comiPhone 13 Pro vs. iPhone 16 Pro: 65+ Upgrades to ExpectSeptember 8, 2024 | macrumors.comMRapport Therapeutics Seeks IPO For CNS Treatment ProgramsMay 22, 2024 | seekingalpha.comProtara Therapeutics Inc (TARA)April 24, 2024 | investing.comiPad ProFebruary 2, 2024 | macrumors.comMEsperion Therapeutics Inc ESPRNovember 5, 2023 | morningstar.comMThe Latest Analyst Ratings for Revance TherapeuticsSeptember 20, 2023 | benzinga.comENLV - Enlivex Therapeutics Ltd.June 6, 2023 | finance.yahoo.comPrelude Therapeutics Insider Trades Send a SignalMay 25, 2023 | benzinga.comGlobal Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives GrowthMay 22, 2023 | benzinga.comRAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingApril 26, 2023 | benzinga.comEarly Adopter of Remote Therapeutic Monitoring Achieves Significant Clinical and Financial OutcomesFebruary 22, 2023 | benzinga.comCadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO)January 22, 2023 | finance.yahoo.comAdvanced Proteome Therapeutics Announces Its Proposed Plan of ArrangementJanuary 19, 2023 | wsj.comPeripheral Arterial Disease (PAD) Therapeutics Market 2023 Size & Segmentation Analysis with Share, Trends till 2028 [ NEW REPORT ]January 18, 2023 | marketwatch.comBusiness & Academia Join Forces To Study Magic Mushroom Therapy For IBS PatientsJanuary 3, 2023 | benzinga.comWhat 5 Analyst Ratings Have To Say About PTC TherapeuticsOctober 17, 2022 | msn.comWhat 6 Analyst Ratings Have To Say About Revance TherapeuticsSeptember 22, 2022 | msn.comPropella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022September 9, 2022 | finance.yahoo.comProthioneTM Capsules Reduced Time to COVID-19 Clinical Resolution and Decreased Viral Load in Phase II Clinical TrialJune 15, 2022 | finance.yahoo.comBristol-Myers To Buy Turning Point Therapeutics In $4.1 Billion Oncology DealJune 3, 2022 | thestreet.comFlagship Pioneering launches protein startup with $75MMay 27, 2022 | bizjournals.com Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTO Media Mentions By Week PRTO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRTO News Sentiment▼0.000.90▲Average Medical News Sentiment PRTO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRTO Articles This Week▼01▲PRTO Articles Average Week Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Inhibikase Therapeutics News Protalix BioTherapeutics News Invizyne Technologies News Achilles Therapeutics News ZIVO Bioscience News bluebird bio News Cyclo Therapeutics News AlloVir News NKGen Biotech News Calidi Biotherapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRTO) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.